Continuous-infusion 5-Fluorouracil versus Xeloda for gastrointestinal cancer: A safety and efficacy observation

作     者：Huihua Gao Xin＇en Huang Jinghua Zhu 

作者机构：Department of Internal Medicine Mai Gao Qjao Hospital Nanjing 210028 China Department of Chemotherapy Jiangsu Cancer Hospital ＆ Research Institute Nanjing 210009 China 

出 版 物：《The Chinese-German Journal of Clinical Oncology》 (中德临床肿瘤学杂志（英文版）)

年 卷 期：2007年第6卷第5期

页      面：447-449页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by grants from the Jiangsu Provincial Personnel Department "the Great of Six Talented Man Peak" Project and the Jiangsu Cancer Hospital Emphasis Project (No. ZK200602) 

主　　题：gastrointestinal cancers 5-Fu Xeloda 

摘      要：Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel （regimen A） versus Xeloda plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel for oral use （regimen B） in patients with gastrointestinal cancers. Methods： Between May 2003 and May 2005, 84 patients diagnosed in Jiangsu Cancer Hospital ＆ Research Institute with locally advanced esophageal, gastnc or colorectal cancer were registered. Regimen A and B consisted of either 5-Fu 0.375 CI days 1-14, every 28 days （n = 44）, or Xeloda 1000 mg twice daily, days 1-14, every 28 days （n = 40）. For both regimen A and B, IV cisplatin 25 mg/m^2 was administered on day 1, 2 and 3 （or Oxaliplatin 75mg/m^2 on day 1, 8 and 15） with or without paclitaxel 60-75 mg/m^2 on day1, 8 and 15. Results： Patients receiving regimen B experienced significantly less stomatitis （P 〈 0.05） and diarrhea （P 〈 0.05）, than those receiving regimen A. Prevalence of nausea/vomiting, alopecia, neutropenia, and hand-foot syndrome without significant difference between two regimens. No treatment related death occurred during study period. Regimen B demonstrates a similar, favorable safety profile in this study. Response rates and rates of clinical benefit for regimen A and B were 40.9%, 40.0% and 43.2%, 65.0% respectively. Conclusion： Based on its improved safety profile and improved rate of clinical benefit, Xeloda has the potential to replace CI 5-FU as an alternative treatment for patients with gastrointestinal cancers.